Futura Medical plc (FUM) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Futura Medical PLC for your Results Investor presentation. Throughout this recorded presentation, investors will be in listen-only mode. Questions are encouraged and they can be submitted at any time using the Q&A tab situated on the right-hand corner of your screen. Just simply type in your questions and press send. Before we begin, I would like to submit the following poll and I would now like to hand you over to CEO Alex Duggan. Good morning. Good morning and a warm welcome to the Futura Medical presentation of its 2025 full year results. I'm Alex Duggan. I've been the CEO since August 2025, and it's my great pleasure to be with you this morning and joined by Futura's two other longstanding executive directors, Angela Hildreth, our finance director and COO, and Ken James, our exec director and head of R&D. Today we're going to cover a number of topics. Angela and I will talk about the full year 2025 performance. Ken will update you on our product and MPD review. I'll summarize some findings from our strategic review and lastly an update on our 2026 key milestone progress. A question and answer session will follow afterwards and we invite anyone to put your questions to us for our for us to answer. Before we get going, can I just draw your attention please to the disclaimers on the previous slide, which will be provided along with this full presentation in the usual way after this event on our website. The key messages we will address today. It will not be a surprise to our shareholders that 2025 has been a year of both challenge and renewal. Financial performance resulting from underlying in-market sales of Eroxon have been disappointing and further details of this and our plans as to how we will improve this performance will follow...